| Document |
Document Title |
|
WO/2024/026455A3 |
The present disclosure relates, in part, to methods and compositions for generating monocytes, macrophages, and/or precursors thereof (such as an induced pluripotent stem cell), comprising (i) a chimeric antigen receptor (CAR); (ii) a po...
|
|
WO/2024/030924A3 |
Provided herein are high affinity dimer CEACAM1 variants. These variants enhance the hCEACAMl mediated modulation of immunity in the treatment of infectious agents, autoimmunity, inflammation and cancer.
|
|
WO/2024/080305A1 |
According to one embodiment of the present invention, a bioactive protein that usually has a low expression level and/or low activity when expressed as a recombinant protein using a host cell such as a CHO cell can be expressed in the fo...
|
|
WO/2024/080637A1 |
The present invention relates to a virus-like particle combination vaccine comprising influenza A virus antigen protein HA, NA or M2e5x. A recombinant universal influenza-virus-like particle vaccine for protection against infection by in...
|
|
WO/2024/079331A1 |
The invention relates to the field of drug delivery for inflammatory diseases, more specifically inflammatory kidney, eye, lung, and intestinal diseases, and kidney, eye, lung and intestinal diseases in general.
|
|
WO/2024/079043A1 |
The invention relates to a method of manufacturing a peptide P, which comprises a step of condensing of an alpha amino acid derivative S-am, which has one unprotected alpha amino group or one unprotected alpha imino group, with a protect...
|
|
WO/2024/078124A1 |
Provided in the present invention is the use of a TDGF1 gene in the preparation of a drug for treating aging-related diseases or reversing cell aging. Compared with the prior art, the present invention has the following advantages: the u...
|
|
WO/2024/081933A1 |
Described herein are methods and compositions for use in generating or promoting an immune response to cancer, comprising administering a combination of an immunotherapy using an immune checkpoint inhibitor, e.g., anti-PD-1 antibodies, a...
|
|
WO/2023/183626A3 |
Described herein are bifunctional peptides, compositions comprising the same, and methods useful for treatment of dental caries that have been treated with silver diamine fluoride. Treatment with bifunctional peptides remineralizes the c...
|
|
WO/2024/078633A1 |
Provided is a gene regulation strategy enabling programmable control over eukaryotic translational initiation and use of said gene regulation strategy for various biomedical purposes including but not limited to therapeutic transgene del...
|
|
WO/2024/026353A3 |
The present invention relates to methods of producing compounds of interest in a recombinant microorganism. In particular, the present invention relates to using a recombinant microorganism comprising a heterologous nucleic acid encoding...
|
|
WO/2024/079292A1 |
This disclosure concerns transcription cassettes comprising nucleic acid molecules comprising a nucleotide sequence encoding AP-4 subunits; vectors comprising said transcription cassettes; pharmaceutical compositions comprising said vect...
|
|
WO/2024/078828A1 |
The present invention relates to a cell-penetrating polypeptide (CPP), which comprises an amino acid sequence that is derived from, or consists of, a portion of a virulence factor, as well as a complex comprising said CPP, a polynucleoti...
|
|
WO/2023/044100A8 |
The present invention provides transgenic animals (e.g., transgenic porcine animals), organs, tissues, and cells derived from the transgenic animals that are particularly useful for xenotransplantation therapies. In particular, the prese...
|
|
WO/2023/235422A3 |
Compositions and methods for making and using engineered myeloid cells that express a chimeric fusion protein for immunotherapy and compositions and methods for making and using engineered T cells that express a chimeric antigen receptor...
|
|
WO/2024/081625A1 |
The present invention provides polypeptides, and polypeptide dimers, comprising a modified flavivirus envelope E polypeptide, wherein the modified flavivirus envelope E polypeptide comprises i) a cysteine residue in a fusion loop epitope...
|
|
WO/2024/050551A3 |
Provided herein are compositions, systems, and methods suitable for in vivo delivery of CAR-encoding expression constructs. Expression constructs engineered to express a heterologous immune receptor under control of an immune cell-specif...
|
|
WO/2024/078479A1 |
The present invention relates to a heterodimeric fusion protein and the use thereof. The heterodimeric fusion protein of the present invention comprises: a first heavy chain, wherein the first heavy chain comprises a first Fc region and ...
|
|
WO/2024/077376A1 |
Acute myeloid leukemia (AML) has not benefited from innovative immunotherapies, mainly because of the lack of actionable immune targets. Novel tumor-specific antigens (TSAs) shared by a large proportion of AML cells are described herein....
|
|
WO/2024/079311A1 |
The present invention relates to the field of immunology. In particular, it relates to novel long cysteine-containing immunogenic peptides, wherein the cysteine has been modified to yield a more stable product while preserving immunogeni...
|
|
WO/2024/078621A1 |
Disclosed are a nanopore mutant protein and a use thereof. The nanopore mutant protein comprises one or more amino acids of the wild-type PHT nanopore protein as represented by SEQ ID NO: 1 being mutated into other amino acids, or knocko...
|
|
WO/2024/081912A1 |
Disclosed herein include methods, compositions, and kits suitable for use in signal amplification. There are provided, in some embodiments, protease-based signal amplification modules. Disclosed herein include amplifier proteins comprisi...
|
|
WO/2024/030950A3 |
The disclosure relates to compositions and methods comprising MSH analogs and cell therapy.
|
|
WO/2024/080843A1 |
The present application relates to a blood-brain barrier permeable fusion protein and use thereof, and provides: a blood-brain barrier permeable fusion protein comprising an IgG antibody, and a helical region binding moiety of transferri...
|
|
WO/2024/081928A1 |
The present invention relates to a hemoglobin protein composition comprising biologically active hemoglobin and less than 2% methemoglobin (metHb) wherein the metHb is maintained below 2% after reoxygenation of hemoglobin. Furthermore, h...
|
|
WO/2024/078584A1 |
Provided are a method for modifying a capsid protein coding sequence of a cap gene of an adeno-associated virus (AAV), and an AAV capsid protein coding sequence obtained via the method. Additionally provided is the use of a modified AAV ...
|
|
WO/2024/081811A2 |
Disclosed herein are conjugates that can effectively deliver a STING agonist. An example conjugate includes a hydrophilic polymer, a diamidobenzimidazole (diABZI), and a linker attaching the diABZI to the hydrophilic polymer. Also disclo...
|
|
WO/2024/081329A1 |
Provides herein are multifunctional polypeptide molecules comprising T cell receptor variable beta-binding moieties and cytokines and methods of treating conditions or diseases in a subject using the same.
|
|
WO/2024/015310A3 |
The invention features a composition including (i) pro-parathyroid hormone (pro-PTH); and (ii) an antibody that specifically binds to pro-PTH.
|
|
WO/2024/079449A1 |
The invention relates to a construct and AAV particle comprising a wildtype NDP nucleic acid sequence or a codon-optimised NDP nucleic acid sequence. The invention further relates to products and methods for the treatment of one or more ...
|
|
WO/2024/081871A1 |
Technologies for the prevention and/or treatment of Shigella infections.
|
|
WO/2024/079531A2 |
The application relates to nucleic acid regulatory elements (NAREs) that are able to enhance expression of genes in the liver. The application further relates to methods employing NAREs and uses of the NAREs. Expression cassettes and vec...
|
|
WO/2024/080306A1 |
According to one embodiment of the present invention, it is possible to efficiently produce a highly-active recombinant protein by expressing, in the form of a fusion protein with serum albumin (SA), a physiologically-active protein havi...
|
|
WO/2024/052542A3 |
There is disclosed a peptide mixture comprising a first, second and third peptide. The first peptide is capable of inducing an immune response against a TGFβR2 -1a frameshift mutant protein, wherein the first peptide comprises i) an imm...
|
|
WO/2024/026284A3 |
Provided for herein are viral particles comprising a heterologous viral glycoprotein and a targeting moiety, wherein the targeting moiety comprises a polypeptide comprising a formula of T-S1, wherein T is a target binding domain and Si i...
|
|
WO/2024/076976A1 |
The disclosure provides polypeptides and polymers, and methods of using the same for reducing the risk of, preventing, or treating inflammation.
|
|
WO/2024/077104A2 |
The present disclosure, at least in part, is based on the discovery of novel anti-Fibroblast activation protein (FAP) antibodies or antigen binding fragments thereof, and genetically modified cells (e.g., iNKT cells) expressing chimeric ...
|
|
WO/2024/074119A1 |
A recombinant collagen and the use thereof in cartilage repair matrix. The recombinant collagen comprises a sequence as shown in SEQ ID No.1; the amino acid sequence of the recombinant collagen comprises N basic repeating units, and the ...
|
|
WO/2024/074571A1 |
Nipah virus (NiV) is a recently emergent, highly pathogenic, zoonotic paramyxovirus. The inventors now designed an anti-CD40 mAb associated either with the Niv G ectodomain protein (Generation-1 vaccine), or the Niv G ectodomain protein ...
|
|
WO/2024/075767A1 |
The purpose of the present invention is to provide: a method for conveniently introducing a gene into a mitochondrion from the outside of a cell; and a method for introducing a nucleic acid having a relatively large size into a mitochond...
|
|
WO/2024/077110A2 |
The present disclosure provides isolated polynucleotides comprising sequences encoding uORF peptides and variants and fragments thereof. The present disclosure also provides constructs and vectors containing the polynucleotides. The pres...
|
|
WO/2024/077256A1 |
The present invention discloses methods and platforms for generating protein binding proteins with specificity for native peptide-MHC (pMHC) complexes. The pMHC binding proteins can be used in bi-specific antibodies or for generating CAR...
|
|
WO/2024/076940A1 |
Nucleic acids are described that encode for triggering receptor expressed on myeloid cells 2 (TREM2) and that can be used in expression constructs, vectors and gene therapies. Also described are methods of using the same for the treatmen...
|
|
WO/2024/077135A1 |
Provided herein are MAGEA1 immunogenic peptides, binding proteins recognizing MAGEA1 immunogenic peptides, and uses thereof.
|
|
WO/2024/075112A1 |
Provided herein are recombinant AAT proteins having high fucosylation levels and enhanced immunomodulatory biological activity as compared to a plasma derived AAT. Further provided are compositions including the same and methods for prep...
|
|
WO/2024/075024A1 |
This invention relates to methods for purifying type II collagen from cartilage tissue. The present invention also relates to a type II collagen composition, and the use of the type II collagen composition as a dietary supplement or trea...
|
|
WO/2024/074584A1 |
The present invention relates to stabilized pre-fusion human parainfluenza virus 3 (HPIV3) F protein, and fragments thereof. The invention also relates to nucleic acid molecules encoding such proteins and fragments, and to the use of the...
|
|
WO/2024/076577A1 |
An aqueous formulation includes a PEDF-derived short peptide (PDSP); a blend of PVP/PVA in different ratios around 8/2 – 2/8; and a tonicity agent, which is preferably non-ionic. The PDSP is preferably 14-39 amino acids long and has th...
|
|
WO/2024/075851A1 |
The purpose of the present invention is to provide a novel nucleic acid construct that induces antibody production. The present invention provides a nucleic acid construct that induces antibody production against a target protein, the nu...
|
|
WO/2024/074105A1 |
The present invention belongs to the field of biopharmaceuticals. Provided in the present invention are keratin YK93-4, a nucleic acid molecule encoding same, an expression vector containing the nucleic acid molecule, a host cell contain...
|
